Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q1 FY26 results · Apr–Jun 2025
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,024.03 crore (up 0.5% from Q1 FY25) and net profit of ₹64.69 crore (up 5.7% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,024.03 | 1,019.11 | +0.5% | 1,055.55 | −3.0% |
| Other income | 26.73 | 6.55 | +308.4% | 17.55 | +52.4% |
| Total income | 1,050.76 | 1,025.66 | +2.4% | 1,073.09 | −2.1% |
| Profit before tax | 95.65 | 87.48 | +9.3% | 75.14 | +27.3% |
| Net profit for the period | 64.69 | 61.21 | +5.7% | 149.61 | −56.8% |
| Attributable to shareholders of the company | 63.48 | 60.17 | +5.5% | 147.62 | −57.0% |
| EPS, basic (₹) | 4.15 | 4.21 | −1.4% | 9.64 | not comparable |
| Net margin (%) | 6.3 | 6.0 | 14.2 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 332.44 | 317.27 | +4.8% | 328.75 | +1.1% |
| Other income | 28.55 | 26.18 | +9.1% | 32.05 | −10.9% |
| Total income | 361.00 | 343.45 | +5.1% | 360.80 | +0.1% |
| Profit before tax | 59.51 | 54.27 | +9.6% | 37.05 | +60.6% |
| Net profit for the period | 44.87 | 41.88 | +7.1% | 27.59 | +62.6% |
| EPS, basic (₹) | 2.93 | 2.93 | +0.0% | 1.80 | +62.8% |
| Net margin (%) | 13.5 | 13.2 | 8.4 |
Consolidated
- Filed with BSE
- 08 Aug 2025, 19:03 IST
- Board meeting
- 08 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2025, 19:03 IST
- Board meeting
- 08 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE